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Background: To assess the effect of previous antibiotic use on the risk of a resistant Escherichia coli
urinary tract infection (UTI), we undertook a case–control study with prospective measurement of out-
comes in 10 general practices in the UK.
Methods: Urinary samples from all patients with symptoms suggestive of UTIs were sought, and those
with a laboratory-proven E. coli infection were interviewed and their medical records examined. Case
patients were those with ampicillin- or trimethoprim-resistant infections and control patients had infec-
tions that were susceptible to antibiotics, including ampicillin and trimethoprim.
Results: Risk of ampicillin-resistant E. coli infection in 903 patients was associated with amoxicillin
prescriptions of 7 days duration in the previous 1 month [odds ratio (OR) 5 3.91, 95% CI 1.64–9.34]
and previous 2–3 months (2.29, 1.12–4.70) before illness onset. For prescriptions <7 days duration,
there was no statistically significant association. Higher doses of amoxicillin were associated with
lower risk of ampicillin resistance. For trimethoprim-resistant E. coli infections, the OR was 8.44 (3.12–
22.86) for prescriptions of trimethoprim of 7 days in the previous month and 13.91 (3.32–58.31) for
the previous 2–3 months. For trimethoprim prescriptions of <7 days, the OR was 4.03 (1.69–9.59) for
the previous month but prescribing in earlier periods was not significantly associated with resistance.
Conclusions: Within the community setting, exposure to antibiotics is a strong risk factor for a resist-
ant E. coli UTI. High-dose, shorter-duration antibiotic regimens may reduce the pressure on the emer-
gence of antibiotic resistance.
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Introduction
Policies to reduce inappropriate antibiotic prescribing in primary
care, thereby reducing the pressure for the emergence and spread
of antibiotic-resistant pathogens, have had some success, but sub-
stantial variations in prescribing rates between- and within-
countries persist.1 – 5 One limiting factor is the scepticism
expressed by many clinicians about the link between their own
antibiotic prescribing and resistant infections in their patients.6
Current policies are based largely on ecological relationships
between prescribing and resistance, and there are only limited
data at the level of the individual patient that are not subject to
the serious selection bias of using routinely collected patient data
and that are adjusted for potential confounders.7,8 Interventions to
improve the quality of antibiotic prescribing could be enhanced if
the link between antibiotic prescribing and being infected with a
resistant, as opposed to a susceptible, organism at the level of the
individual patient could be established, and if the influence of
time from prescription to onset of resistant infection, frequency
of antibiotic use and duration and dose of antibiotic could be
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quantified. To address this evidence gap, we undertook a nested
case–control study of incident cases of clinically suspected
urinary tract infections (UTIs) presenting in general practice.
Materials and methods
General practices in South Wales representing the range of geogra-
phy, social economic deprivation and prescribing rates were
recruited and stratified by quartiles for prescribing rates, size, depri-
vation score and rate of submitting urine samples. Deprivation was
assessed by the Townsend score,9 a measure derived from census
data, based on unemployment, car ownership, overcrowding and
type of housing tenure. Five practices already participating in sur-
veillance were invited to participate and a further five were selected
to ensure a balance across these parameters.
On the basis of the local data, we estimated that 20 000 UTI
cases would present to these practices over 18 months, of which at
least 2000 would yield Escherichia coli infections in urine speci-
mens. From the Wales GP Morbidity Study, we expected that 20%
of these specimens would be duplicates. We estimated that we
would obtain a 60% response rate from all eligible participants and
hence expected approximately 960 patients to take part in our study.
After the pilot study, it was estimated that 38% would be susceptible
to all antibiotics, defining the controls, and that 50% would be
resistant to ampicillin and 20% to trimethoprim. This would give
approximately 500 cases resistant to ampicillin, 200 cases resistant
to trimethoprim and 380 controls. Assuming that at least 13% of the
population would have had the relevant antibiotic prescribed in the
previous year, the study would have at least 90% power for detecting
an odds ratio (OR) of 2 for the association between prior antibiotic
prescribing and a UTI resistant to that antibiotic.
From July 2002 to March 2004, we sought to enrol all patients
presenting at the selected practices with a clinically suspected UTI.
Health professionals obtained written informed consent and asked
patients to submit urine specimens. Copies of the laboratory results
were sent simultaneously to the research team and the practices. A
research nurse who was blind to the laboratory results administered
a questionnaire about treatment of the current infection, outcomes,
history of prior antibiotic exposure, comorbidity, illness history,
exposure to others who take antibiotics either in the home or work,
household details and socioeconomic factors. Informed consent was
sought to review medical records to identify antibiotics prescribed
in the year before the UTI for both the patients and other members
of their household. The study was approved by the Local Research
Ethics Committee in January 2002.
Study patients were those who presented with a new episode of
UTI and a laboratory-confirmed (.105 organisms per mL) E. coli
infection; catheterized patients and those with UTI in the previous
4 weeks were excluded. Susceptibilities to trimethoprim, ampicillin,
co-amoxiclav, cefalexin, ciprofloxacin and nitrofurantoin were
reported using the BSAC method.10 Case patients were those with
E. coli resistant to ampicillin or trimethoprim and controls were
patients whose E. coli were susceptible to all six antibiotics tested.
A sample of 139 isolates from the 3 participating NHS laboratories
were retested at the University Antibiotic Reference Laboratory and
all susceptibilities were confirmed.
Statistical analysis
The primary hypothesis was that the odds of being infected with an
antibiotic-resistant, compared with an antibiotic-susceptible, E. coli
would be modified by prior use of the antibiotic to which the
organism was resistant and that the extent of this modification
would depend on how long before the infection the prior use
occurred. A secondary hypothesis was that the odds would depend on
the duration of the prescription. These hypotheses were assessed by
calculating adjusted ORs using multivariate logistic regression with
SPSS v12. The ORs were adjusted for the following clinically rel-
evant variables: age (categorical variable divided into seven
groups), gender, practice and previous bladder operation. In order to
explore the parameters of ‘antibiotic pressure’, we recorded the
number of prescriptions in the year before the date of the sample for
the current UTI and also the date, dosage and duration of each pre-
scription. The duration of a prescription was classified into ‘,7
days’ and ‘at least 7 days’. We defined the usage to be concurrent if
the date of the prescription was after the date of onset of symptoms.
We used the Nagelkerke coefficient of determination to estimate the
percentage of variation in resistance explained by the logistic
regression models. The goodness-of-fit of each model was assessed
using the Hosmer and Lemeshow test. The results were checked
using multilevel modelling to account for the hierarchical nature of
the sampling but these had very little effect.
Results
Submission of urine specimens by the 10 study practices averaged
8059 per year during the study period. In all, there were 2124
laboratory-confirmed cases of E. coli, of which 1508 met the
inclusion criteria (496 were duplicate samples and 120 patients
did not meet the clinical criteria). Questionnaires were completed
for 932 (62%) and medical records were checked for 903 (97%)
of these patients. Participating patients were similar in age,
gender and general practice to those who declined to participate.
Ampicillin resistance
Of the 903 patients, 359 (40%) had E. coli infections resistant to
ampicillin and were the cases for this part of the study; 489
(54%) patients had E. coli infections susceptible to all antibiotics
tested and were the controls. Two hundred and seventeen (24%)
had been prescribed 294 courses of amoxicillin during the pre-
vious year. Of these, 68% were for respiratory tract infection,
15% for UTI, 3% for oral infection and 14% for other reasons.
Patients with ampicillin-resistant E. coli infections were sig-
nificantly more likely to have been prescribed amoxicillin in the
previous year compared with controls (OR 1.70, 1.24–2.32)
(Table 1). There was a significant trend in ORs for length of
time between the most recent prescription and the date of the
sample (x2 ¼ 17.3, P , 0.0001). For concurrent prescribing
compared with no prescribing, the OR was 9.34 (1.12–78.01),
falling to 2.59 (1.25–5.40) for the previous month and to 0.90
(0.42–1.93) for 10–12 months previously.
The OR for patients prescribed amoxicillin for at least 7 days
in the previous year compared with no antibiotic was 1.79 (1.24–
2.58); for ,7 days duration, the OR was 1.20 (0.65–2.19).
Ampicillin resistance was significantly associated with the
number of amoxicillin prescriptions in the previous 12 months
(x2 ¼ 16.3, P , 0.0001). The ORs increased from 1.44 (1.02–
2.05) for one prescription, compared with none, to 2.28 (1.16–
4.48) for two prescriptions and to 5.71 (1.58–20.65) for three or
more prescriptions.
To investigate the effect of dosage separate from frequency
of prescription we compared data from the 171 patients who had
Resistance and prior antibiotics in UTI
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received only one prescription in the previous year with those
patients who had not received a prescription. The OR for
250 mg of amoxicillin three times daily compared with none
was 2.07 (1.39–3.06) but was 0.91 (0.49–1.70) for 500 mg
three times daily. The OR comparing low dose with high dose
was 2.19 (1.08–4.41).
Interactions between the duration and timing of the most
recent amoxicillin prescription were investigated using logistic
regression to adjust for age, gender, practice and previous
bladder surgery. In the group of patients where the most recent
prescription was for ,7 days, none of the adjusted ORs was
found to be significantly increased (Table 2). The OR was 3.35
for prescribing in the previous month, similar to the unadjusted
OR, but in both cases the confidence interval included 1. There
was no trend with increasing time since prescription. However,
for the group in whom the most recent prescription was for 7
days, there was a statistically significant increased risk with pre-
scribing in the previous month (OR 3.91, 1.64–9.34) and for 2–
3 months previously (OR 2.29, 1.12–4.70). The results of the
Hosmer and Lemeshow test showed that there was no significant
lack-of-fit in the logistic regression model (P ¼ 0.714).
Associations with the total duration of prescriptions in each
period were also investigated; results were very similar to those
of the most recent prescription. The number of courses pre-
scribed in the previous year did not add significantly to the fit of
the model but the dose of amoxicillin could not be explored
in the model because of small numbers. We estimated that 6%
of the variation in ampicillin resistance was explained by
prescribing for amoxicillin in the previous year.
Trimethoprim resistance
Of the 903 patients, 154 (17%) had E. coli infections resistant to
trimethoprim and were the cases for this part of the study; 489
(54%) were susceptible to all antibiotics tested and were the
controls. Two hundred and seven (23%) had been prescribed at
least one course of trimethoprim in the previous year; 83% of
these were for UTIs.
Patients with trimethoprim-resistant infections were signifi-
cantly more likely to have been prescribed trimethoprim in the
previous year compared with controls (OR 2.39; 1.62–3.53)
(Table 3). There was a significant trend in ORs for length of
time between the most recent prescription and the date of the
sample (x2 ¼ 30.5, P, 0.0001). The OR was 4.93 (2.61–9.30)
for concurrent prescribing compared with no prescribing, falling
to 4.11 (0.57–29.53) for the previous month to 1.06 (0.49–2.27)
for 4–6 months previously.
There was a significantly increased risk of resistance associ-
ated with length of course of trimethoprim compared with no
prescription, with ORs of 4.62 (2.73–7.82) for 7 days, and
1.60 (0.92–2.77) for ,7 days. The ratio of these ORs was 2.89
(1.45–5.79), showing that the OR for the longer course was
significantly greater than that for the short course prescription.
Table 1. Prior amoxicillin prescriptions and risk of ampicillin-resistant E. coli UTIs
Variable Category Resistant/susceptible OR 95% CI
Timing of amoxicillin
amoxicillin in previous 12 months no 250/389 ref
yes 109/100 1.70 1.24–2.32
time period of most recent amoxicillin
previous to UTI
1 month (prescribed after
reported date of onset
concurrent use)
6/1 9.34 1.12–78.01
1 month (prescribed before
reported date of onset
previous use)
20/12 2.59 1.25–5.40
2–3 months 28/21 2.07 1.15–3.73
4–6 months 19/22 1.34 0.71–2.53
7–9 months 25/25 1.56 0.87–2.77
10–12 months 11/19 0.90 0.42–1.93
Duration
duration of amoxicillin prescription nearest
to UTI
none 250/389 ref
,7 days 20/26 1.20 0.65–2.19
7þ days 76/66 1.79 1.24–2.58
Number of amoxicillin courses
number of amoxicillin courses in previous
12 months
0 250/389 ref
1 76/82 1.44 1.02–2.05
2 22/15 2.28 1.16–4.48
3þ 11/3 5.71 1.58–20.65
Dose of amoxicillin
amoxicillin dose risk of 250 mg compared
with 500 mg, both three times a day, in
previous 12 months for subjects who had a
single prescription
none 250/389 ref
low dose 69/52 2.07 1.39–3.06
high dose 17/29 0.91 0.49–1.70
Hillier et al.
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Table 2. Logistic regression models relating prior prescriptions to risk of antibiotic-resistant E. coli UTIs
Ampicillin Trimethoprim
proportion-resistant unadjusted ORa (95% CI) adjusted ORb (95% CI) proportion-resistant unadjusted ORa (95% CI) adjusted ORb (95% CI)
No antibiotics 250/639 (39.1) reference reference 94/480 (19.6) reference reference
Duration ,7 days
previous month 6/9 (66.7) 3.11 (0.77, 12.56) 3.35 (0.82, 13.72) 11/25 (44) 3.23 (1.42, 7.33) 4.03 (1.69, 9.59)
previous 2–3 months 4/10 (40) 1.04 (0.29, 3.71) 1.04 (0.28, 3.80) 3/10 (30) 1.76 (0.45, 6.93) 1.68 (0.40, 7.09)
previous 4–6 months 3/8 (37.5) 0.93 (0.22, 3.94) 0.65 (0.12, 3.44) 2/19 (10.5) 0.48 (0.11, 2.13) 0.49 (0.10, 2.27)
previous 7–9 months 5/13 (38.5) 0.97 (0.31, 3.01) 0.92 (0.29, 2.94) 4/16 (25.0) 1.37 (0.43, 4.34) 1.97 (0.59, 6.61)
previous 10–12 months 2/6 (33.3) 0.78 (0.14, 4.28) 0.90 (0.16, 5.05) 1/5 (20) 1.03 (0.11, 9.29) 1.46 (0.15, 14.13)
Duration 7þ days
previous month 17/25 (68) 3.31 (1.41, 7.78) 3.91 (1.64, 9.34) 14/22 (63.6) 7.19 (2.93, 17.63) 8.44 (3.12, 22.86)
previous 2–3 months 22/36 (62.2) 2.45 (1.23, 4.87) 2.29 (1.12, 4.70) 8/11 (72.7) 10.95 (2.85, 42.07) 13.91 (3.32, 58.31)
previous 4–6 months 15/31 (41.1) 1.46 (0.71, 3.00) 1.43 (0.67, 3.05) 6/18 (33.3) 2.05 (0.76, 5.61) 2.32 (0.80, 6.75)
previous 7–9 months 15/30 (50) 1.56 (0.75, 3.24) 1.45 (0.68, 3.07) 5/9 (55.6) 5.13 (1.35, 19.49) 5.50 (1.37, 22.15)
previous 10–12 months 7/20 (35) 0.84 (0.33, 2.13) 0.75 (0.29, 1.95) 3/8 (37.5) 2.46 (0.58, 10.49) 2.84 (0.60, 13.36)
aReference category is no antibiotics.
bAdjusted for age, sex, practice and bladder operation.
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The risk of trimethoprim resistance was significantly associ-
ated with the number of prescriptions in the previous 12 months
(x2 ¼ 25.5, P , 0.0001). The ORs increased from 2.08 (1.34–
3.22) for one prescription to 2.05 (0.85–4.94) for two prescrip-
tions and 7.53 (2.71–20.88) for three or more prescriptions.
In a logistic regression model, adjusting for age, gender, prac-
tice and previous bladder surgery, for those patients who were
most recently prescribed trimethoprim for ,7 days, a prescrip-
tion in the previous month was associated with an increased risk
(Table 2), with adjusted OR of 4.03 (1.69–9.59). Earlier time
periods were not significantly associated with an increased risk
and there was no clear trend. For patients who had prescriptions
with duration of at least 7 days, there was a statistically signifi-
cant increased risk of resistance for prescriptions within the pre-
vious month (adjusted OR 8.44, 3.12–22.86) and the previous
2–3 months (adjusted OR 13.91, 3.32–58.31). ORs were above
2 for the 4–12 months period but lower confidence limits were
above 1 only for the 7–9 months period (OR 5.50, 1.37–22.15).
The results of the Hosmer and Lemeshow test showed that there
was no significant lack-of-fit in the logistic regression model
(P ¼ 0.742). Associations with the total duration of prescriptions
in each period were also investigated; results were very similar
to those of the most recent prescription. The number of courses
did not add significantly to the fit of the model. We estimate
that 19% of the variation in trimethoprim resistance was
explained by prescribing for trimethoprim in the previous year.
Other potential risk factors
We considered associations with usage of other antibiotics.
There was no statistically significant association between
trimethoprim prescribing in the previous year and ampicillin
resistance (OR 1.20, 0.87–1.66) [Table S1, available as
Supplementary data at JAC Online (http://jac.oxfordjournals.org/)].
The association between amoxicillin prescribing and trimetho-
prim resistance approached statistical significance (OR 1.51,
0.995–2.28). These remained non-significant when added into
the multivariate models. Patients prescribed cephalosporins in
the year prior to the UTI had a significantly increased risk of tri-
methoprim resistance (OR 2.10, 1.13–3.90) and of ampicillin
resistance (OR 1.99, 1.21–3.28). Cephalosporin usage was mar-
ginally significant when added into each multivariate model but
did not alter the effect sizes for either amoxicillin prescribing or
trimethoprim prescribing. Further analyses of number, timing
and duration of cephalosporin prescriptions and associations
with resistance were not possible due to small numbers. For
those patients who were prescribed a b-lactam (excluding amox-
icillin and cephalosporins), the risk of ampicillin resistance was
increased but was not statistically significant (OR 1.32, 0.90–
1.92) and similarly for trimethoprim resistance (OR 1.22, 0.74–
2.01). This remained non-significant when added into each
multivariate model and did not alter effect sizes for other
variables.
Neither ampicillin nor trimethoprim resistance was significantly
associated with gender [Table S2, available as Supplementary data
at JAC Online (http://jac.oxfordjournals.org/)] and there was no
consistent pattern in associations between either age or social class
and resistance. Neither ampicillin- nor trimethoprim-resistant
infections were significantly associated with an infectious illness
or a previous UTI (Table S2). Trimethoprim resistance was associ-
ated with previous use of a catheter (OR 1.55, 1.03–2.35) and
previous bladder surgery (OR 2.05, 1.17–3.60); there was an
Table 3. Prior trimethoprim prescriptions and risk of trimethoprim-resistant E. coli UTIs
Variable Category
Resistant/
susceptible OR 95% CI
Timing of trimethoprim
trimethoprim in previous 12 months no 94/386 ref
yes 60/103 2.39 1.62–3.53
time period of most recent trimethoprim
previous to UTI
1 month prescribed after
reported date of onset
(concurrent use)
24/20 4.93 2.61–9.30
1 month (prescribed before
reported date of onset
previous use)
2/2 4.11 0.57–29.53
2–3 months 11/14 3.23 1.42–7.33
4–6 months 9/35 1.06 0.49–2.27
7–9 months 9/17 2.17 0.94–5.03
10–12 months 5/15 1.37 0.49–3.86
Duration of trimethoprim
duration of trimethoprim prescription
nearest to UTI
none 94/386 ref
,7 days 21/54 1.60 0.92–2.77
7þ days 36/32 4.62 2.73–7.82
Number of trimethoprim courses
number of trimethoprim courses in
previous 12 months
0 94/386 ref
1 41/81 2.08 1.34–3.22
2 8/16 2.05 0.85–4.94
3þ 11/6 7.53 2.71–20.88
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increased risk of borderline significance between previous bladder
surgery and ampicillin resistance (OR 1.57, 0.98–2.52).
Associations with other comorbidities were not statistically signifi-
cant [Table S2, available as Supplementary data at JAC Online
(http://jac.oxfordjournals.org/)].
Discussion
We found that compared with infection with a susceptible E. coli
both ampicillin- and trimethoprim-resistant E. coli UTIs were
associated with amoxicillin and trimethoprim prescriptions of 7
or more days duration in the previous 3 months, but there was no
evidence that demographic characteristics, comorbidities or pre-
vious clinical history (other than previous bladder operations or
use of catheters) were risk factors. In general, the ORs were
higher for trimethoprim compared with ampicillin resistance,
although the relationships with time were similar. For prescrip-
tions of ,7 days duration, the association was significant only
for the following month. The frequency of prescription did not
improve the explanatory power of the models. Numbers were too
small to include dosage in the models, but in univariate analyses
the high dose of ampicillin was associated with a significantly
lower risk of resistance in comparison with the low dose. It is
possible that the cumulative pressure of prescribing throughout a
period has a greater effect than the most recent prescription, but
the results were very similar when the total duration of prescrip-
tions was used. As the majority of patients had a single prescrip-
tion, there was limited power for investigating this.
We found some evidence that usage of one antibiotic is
associated with resistance to another. For ampicillin usage and
trimethoprim resistance, and trimethoprim usage and amoxicillin
resistance, the association was not statistically significant but the
OR was raised. However, for both ampicillin and trimethoprim
resistance, there was a significant association with usage of
cephalosporins. Patients who had used those were more likely to
have had previous UTIs and their clinical history may have
influenced prescribing. The study was not powered to look at
cephalosporin resistance, and only four patients who had used
cephalosporins in the last year were resistant to cefalexin, so
that conclusions regarding cephalosporin usage and resistance
cannot be drawn.
The results on usage of one antibiotic and resistance to
another do raise interesting questions about the resistance mech-
anisms involved; do they arise from linkage of genetic material,
for example, from plasmids? This cannot be answered by this
study, however.
The validity of our findings depends on the accurate desig-
nation of cases and controls, defined, respectively, by E. coli
resistance and susceptibility to antibiotics. Testing was per-
formed in quality-controlled accredited laboratories and there
was 100% agreement on re-testing for ampicillin and trimetho-
prim susceptibilities at the antibiotic reference laboratory. The
choice of controls as subjects with UTIs susceptible to all anti-
biotics was determined by our aim to examine factors that led to
resistant infections, taking into account underlying conditions
and procedures that might predispose to UTIs. Harris et al.11
have argued that such a choice of controls could lead to bias,
because antibiotics for respiratory infections could prevent those
with a urinary tract colonization from developing a UTI, and
therefore such people would be excluded from being controls.
This is rather speculative, not supported by any data and is unli-
kely to have a significant effect on the results. Measurement of
exposure is also important. We equated previous antibiotic pre-
scriptions with exposure to antibiotics. We do not know whether
the patients actually took the antibiotics or for how long. Recall
of antibiotics used in the previous 12 months was too difficult
for many patients and we had to rely on prescription data from
their medical records.
The relationship between antibiotic prescribing and the risk
of resistant infections has not been well characterized previously
at the individual level for patients in the community. Our sys-
tematic review of community-acquired UTIs in 20027 identified
only 10 studies that analysed individual data; a recent update
[Table S4, available as Supplementary data at JAC Online
(http://jac.oxfordjournals.org/), January 2001–week 26 of 2005]
identified a further 7 studies.12 – 18 Several studies lacked clear
case definitions, were often underpowered and did not always
control for important confounding factors, and it was not always
clear if exposure to antibiotics excluded antibiotics prescribed
for the incident UTI. Many relied on routinely submitted urine
specimens and so are subject to selection bias, as these samples
are likely to include a higher proportion of older, more severely
affected patients and patients with failed antibiotic treatment and
other special risk factors such as bladder surgery. Findings,
therefore, may not be representative of the general population
consulting in general practice with UTIs.19 Several studies
involved highly selected groups of patients, such as those attend-
ing outpatient clinics and emergency departments,15 – 18 used
limited data on antibiotic usage13,14 or combined results from a
mixture of different bacterial pathogens.15
There are, however, several studies directly relevant to this
one. Pedersen et al.20 linked Danish patients with
community-acquired E. coli bacteraemia to prior prescribing of
any antibiotic and found ORs for ampicillin resistance of 2.6
(1.6–4.3), 2.3 (1.4–4.0) and 1.6 (0.8–2.9) for the previous
month, 2–3 months and 4–6 months, respectively, compared
with no prior use, and for trimethoprim resistance of 4.0 (2.0–
7.9), 2.7 (1.3–5.9) and 1.5 (0.6–3.9). They did not examine
individual antibiotics, nor their duration or dose. However, their
ORs for a different patient population are similar to those of our
study on UTIs looking at specific prior use of amoxicillin and
trimethoprim.
Steinke et al.12 linked records of routine hospital laboratory
and community prescribing data in Scotland and found that
Gram-negative bacteria were four times as likely to be
trimethoprim-resistant if trimethoprim had been prescribed
during the preceding 6 months. These results were not specific to
E. coli but are similar to those we report here, as were those of a
later record linkage study by Donnan et al.,17 who examined tri-
methoprim resistance in relation to the timing of previous use of
trimethoprim. Overall, they found ORs of 1.22 (1.16–1.28) for
prior use, 9.19 (6.35–13.3) for 8–15 days before the incident
UTI and 2.93 (2.20–3.89) for 16–30 days previously, falling to
1.45 (1.03–2.05) for 4–6 months previously. It is possible that
the 8–15 days period included concurrent prescribing, which
was identified in our study through patient interviews.
Our study has major methodological strengths compared with
these previous studies. We attempted to obtain data on all UTIs
presenting at general practices, not just those submitted routinely
for laboratory testing, which are likely to be a highly selected
subset of all cases. By using a detailed questionnaire, backed up
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by an examination of GP records, we were able to obtain a
detailed medical history to rule out concurrent prescribing and
to examine the influence of comorbidities and other sources of
exposure to antibiotics. Although we found a strong association
between prescriptions and subsequent resistant infection for both
ampicillin and trimethoprim, the proportion of variation that can
be explained in the logistic model is not high. Most resistant
E. coli infections cannot be explained by use of antibiotics by
the patients nor by proximity to others taking antibiotics at
home or visiting or working in settings where antibiotic use is
likely. UTIs generally originate from the patient’s own intestine
and antibiotics select for resistant organisms in the E. coli in the
gut. One possible explanation for the association between resist-
ant E. coli infections and treatment with lower doses of anti-
biotics is that lower doses may not be as effective at clearing
bacteria with intermediate resistance and thus may allow this
population to proliferate. Hay et al.21 found that E. coli ident-
ified as contaminants of urine samples from asymptomatic
adults were more likely to be resistant to amoxicillin and/or tri-
methoprim if an antibiotic had been prescribed in the previous
2 months, although this effect did not persist over 12 months,
and showed a dose–response relationship in the case of tri-
methoprim use. The potential role of food as a vehicle for anti-
biotic resistance is another option to be considered.22
In summary, we have found that previous prescribing of
amoxicillin and trimethoprim for 7 days or more in general prac-
tice is associated with an increased risk of ampicillin and tri-
methoprim resistance in UTIs in the following 3 months and
that in the case of ampicillin a higher prescribed dose may
reduce this risk. Interventions to deliver more appropriate pre-
scriptions to limit antibiotic resistance should therefore consider
the benefits of higher dose, shorter duration courses.
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